News29/01/2026
Formation Bio licenses miR-124 program from CTFH
Formation Bio, Inc. →Formation Bio acquired worldwide rights excluding Greater China to FHND5032, an oral miR-124 activator for autoimmune disease, from Jiangsu Chia Tai Feng Hai Pharmaceutical. The program was to be housed in subsidiary Kenmare Bio. CTFH receives a minority interest in Kenmare, an upfront payment, potential milestones totaling up to [figure hidden] with the upfront payment, and royalties on possible future sales. The disclosed ceiling is contingent consideration, not an amount paid or parent-company valuation. Formation planned clinical entry during 2026 and described using its Forge platform for development strategy.